Shares of BeyondAirInc . (NASDAQ:XAIR) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 1-year consensus target price of $14.00 for the company and are forecasting that the company will post ($0.22) earnings per share for the current quarter, according to Zacks. Zacks has also given BeyondAirInc . an industry rank of 99 out of 256 based on the ratings given to related companies.
NASDAQ:XAIR traded down $0.19 during trading hours on Friday, hitting $5.05. 1,698 shares of the company traded hands, compared to its average volume of 12,483. The stock has a market cap of $53.43 million, a P/E ratio of -6.01 and a beta of -0.27. BeyondAirInc . has a twelve month low of $3.11 and a twelve month high of $6.25.
BeyondAirInc . Company Profile
Beyond Air, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.